J.W. Cole Advisors Inc. Raises Stake in Eli Lilly and Company (NYSE:LLY)

J.W. Cole Advisors Inc. raised its position in Eli Lilly and Company (NYSE:LLY) by 1.7% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,343 shares of the company’s stock after acquiring an additional 157 shares during the quarter. J.W. Cole Advisors Inc.’s holdings in Eli Lilly and Company were worth $8,459,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of LLY. Tidemark LLC acquired a new position in Eli Lilly and Company in the 4th quarter valued at $29,000. Core Wealth Advisors Inc. increased its stake in Eli Lilly and Company by 188.2% in the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after buying an additional 32 shares during the period. Lynx Investment Advisory acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth $32,000. LGT Financial Advisors LLC acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth $36,000. Finally, Frank Rimerman Advisors LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth $37,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of recent analyst reports. Barclays upped their price target on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. Bank of America upped their price target on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Deutsche Bank Aktiengesellschaft raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and upped their price target for the stock from $725.00 to $1,025.00 in a research note on Monday, August 12th. Jefferies Financial Group upped their price target on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research note on Monday, June 24th. Finally, Truist Financial reiterated a “buy” rating and issued a $1,000.00 price objective (up from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $977.35.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 9,671 shares of the stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $902.67, for a total transaction of $8,729,721.57. Following the transaction, the insider now directly owns 97,574,139 shares in the company, valued at approximately $88,077,248,051.13. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold a total of 646,878 shares of company stock worth $591,465,138 in the last three months. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $923.71 on Friday. The firm has a market cap of $877.92 billion, a price-to-earnings ratio of 136.04, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The company’s 50-day moving average is $897.12 and its two-hundred day moving average is $832.88. Eli Lilly and Company has a 12-month low of $516.57 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The company had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. Research analysts expect that Eli Lilly and Company will post 16.49 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th were issued a dividend of $1.30 per share. The ex-dividend date was Thursday, August 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.56%. Eli Lilly and Company’s payout ratio is currently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.